A Smart + Strong Site
Subscribe to:
Newsletters
POZ magazine
JOIN AIDSMEDS YouTube

Back to home » Treatment News » Top Stories

Most Popular Stories
Undetectable Viral Load Essentially Eliminates Transmission Risk in Straight Couples
FDA Approves New Single-Tablet HIV Regimen, Triumeq
Life Expectancy for Young People With HIV Is Nearly Normal
A 15-Year Jump in Life Expectancy for People With HIV
Scientists Devise Method of Snipping HIV From Immune Cells
Monkey HIV Vaccine Success Opens Door for Human Trials
HIV Combo Pill Less Toxic Thanks to New Form of Tenofovir
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Shingles
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to news@aidsmeds.com.

Click here for more news


emailprint

August 13, 2013

FDA Approves HIV Drug Tivicay (Dolutegravir)

The U.S. Food and Drug Administration (FDA) has approved ViiV Healthcare’s Tivicay (dolutegravir), the second approved antiretroviral (ARV) in the integrase strand transfer class after Isentress (raltegravir), MedPage Today reports. The FDA declined to approve a third drug, elvitegravir, as an individual agent in the same class. It has already been approved as a component of the “Quad” pill, Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir), and may eventually be approved as an individual agent.

The FDA gave the green light for Tivicay’s use in both treatment-naive as well as treatment-experienced people with HIV, including those who have taken Isentress. The agency also approved the ARV for use in children ages 12 and up who weigh at least 40 kilograms (88 pounds) and have not taken integrase inhibitors before.

Before making its decision, the FDA considered four Phase III clinical trials including 2,557 participants who were randomly given Tivicay or Isentress in combination with other ARVs, or they were given Atripla (efavirenz/emtricitabine/tenofovir).

Tivicay suppressed HIV at rates equivalent to or better than Isentress. Tivicay is considered a promising alternative because of its once-a-day, 50 milligram dosing, compared with twice-a-day, 400 mg dosing for Isentress.

Tivacy’s common side effects included insomnia and headache. Serious side effects included hypersensitivity reactions and abnormal liver function among those coinfected with HIV and hepatitis B or C.

ViiV Healthcare is a joint effort of GlaxoSmithKline and Pfizer, established in 2009 to pursue advancements in HIV care.



To read the MedPage Today article, click here.

To read the FDA release, click here.

Search: ViiV Healthcare, GSK, GlaxoSmithKline, Tivicay, dolutegravir, Isentress, raltegravir, FDA, Stribild, elvitegravir, cobicistat, emtricitabine, tenofovir, HIV, Quad


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team reviews all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)


[Go to top]

Quick Links
About HIV and AIDS
The Cure
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Disclosure
Lipodystrophy
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Blogs
Conference Coverage
Health Services Directory
POZ Magazine
AIDSmeds on Twitter


Conference Coverage

XX International AIDS Conference
(AIDS 2014)
Melbourne, Australia
July 20 - 25, 2014


21st Conference on Retroviruses and Opportunistic Infections
(CROI 2014)
Boston, MA
March 3 - 7, 2014


7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
(IAS 2013)
Kuala Lumpur, Malaysia
June 30 - July 3, 2013


more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.